Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

Inclusion Criteria: * Men and women ≥15 years of age * Diagnosis of chronic myeloid leukemia in any phase that used dasatinib at any time between January 2008 and November 2014 * Have received dasatinib as part of their first-line or second-line treatment for at least 45 days Exclusion Criteria: * Patients who received dasatinib as part of any clinical trial * Patients who do not have complete data on the data collection sheet * Patients who do not have medical records available at the moment of the data verification